Myringotomy in the Junbo mouse model of chronic otitis media alleviates inflammation and cellular hypoxia by Bhutta, Mahmood F et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Myringotomy in the Junbo mouse model of chronic otitis media
alleviates inflammation and cellular hypoxia
Citation for published version:
Bhutta, MF, Cheeseman, MT & Brown, SDM 2014, 'Myringotomy in the Junbo mouse model of chronic otitis
media alleviates inflammation and cellular hypoxia' The Laryngoscope, vol. 124, no. 9, pp. E377-E383. DOI:
10.1002/lary.24698
Digital Object Identifier (DOI):
10.1002/lary.24698
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
The Laryngoscope
Publisher Rights Statement:
This article has been accepted for publication and undergone full peer review but has not been through the
copyediting, typesetting, pagination and proofreading process which may lead to differences between this
version and the Version of Record.
Please cite this article as doi: 10.1002/lary.24698
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
 Myringotomy in the Junbo mouse model of chronic otitis media 
alleviates inflammation and cellular hypoxia 
 
 
Mahmood F Bhutta1,2,3,4 DPhil FRCS 
Michael T Cheeseman2,5 DVM PhD MRCVS FRCPath 
Steve DM Brown2 PhD FMedSci 
 
 
1. UCL Ear Institute, 332 Grays Inn Road, London, UK 
2. MRC Harwell, Harwell Science and Innovation Campus, Oxfordshire, UK 
3. Nuffield Department of Surgical Sciences (University of Oxford), John Radcliffe 
Hospital, Oxford, UK 
4. Department of Otolaryngology, Barts Health NHS Trust, London, UK 
5. Neurobiology Division, Roslin Institute (University of Edinburgh), Edinburgh, UK 
 
 
 
 
The experimental work presented herein was undertaken at MRC Harwell. 
 
Running title: Myringotomy in mouse alleviates hypoxia 
 
 
 
Financial Support: 
MFB was supported by a research fellowship from the Wellcome Trust.  Additional funding 
was provided by the Medical Research Council. 
 
Conflict of interest: 
Nothing to declare 
 
 
 
 
 
Correspondence: 
Mahmood Bhutta 
m.bhutta@doctors.org.uk 
Nuffield Department of Surgical Sciences (University of Oxford), Room 6607, Level6, John 
Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK 
Tel: +441865 231055 
 
Presented at the Otorhinolaryngology Society meeting, March 16th 2012, London, UK.  
Winner of the Angell-James Prize. 
 
  
The American Laryngological, Rhinological and Otological Society, Inc. 
This article has been accepted for publication and undergone full peer review but has not been
through the copyediting, typesetting, pagination and proofreading process which may lead to
differences between this version and the Version of Record. Please cite this article as
doi: 10.1002/lary.24698
 Abstract 
Objective 
Ventilation of the chronically inflamed middle ear is a key outcome in functional middle ear 
surgery. Grommets eliminate middle ear effusion, but there is also evidence that they 
downregulate inflammation.  The reason for this is not understood, but there is little to 
suggest alteration in Eustachian tube ventilatory capacity.  Previous work has shown that 
the Junbo mouse model of chronic otitis media has hypoxic middle ear mucosa and bulla 
fluid leucocytes.  Here we explore if surgical ventilation may alleviate chronic otitis media 
through downregulation of hypoxia. 
 
Study Design 
Surgical intervention on a mouse model of disease. 
 
Methods 
We established patency of myringotomy incision as 5 days in wild-type mice.  We 
performed unilateral myringotomy on three cohorts of mice: 10 wild type controls, 12 Junbo 
mice, and 15 Junbo mice with additional removal of middle ear effusion.  A small cohort of 
these mice were labeled in-vivo by intraperitoneal injection of pimodinazole to identify 
tissue hypoxia.  Tissues were assessed for mucoperiosteal thickening and pimodinazole 
labeling, comparing operated to non-operated ears. 
 
Results 
Ventilation of the inflamed Junbo middle ear revealed significant reduction in inflammatory 
thickening associated with loss of pimodinazole labeling, suggesting resolution of cellular 
hypoxia. 
 
Conclusion 
Surgical ventilation may achieve therapeutic effect through alleviation of cellular hypoxia in 
the chronically inflamed middle ear.  Targeted molecular therapy of hypoxia signaling may 
offer future alternative therapy for chronic OM. 
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N/A
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Introduction 
 
The middle ear evolved when our evolutionary predecessors moved from an aquatic to a 
terrestrial existence.  The development of a gas-filled pocket next to the cochlea overcame 
air-fluid impedance mismatch, and so enabled audition of air-borne sound1.   In mammals 
maintenance of this gas pocket is primarily achieved through gaseous exchange across the 
mucosal epithelium of the postero-superior middle ear cleft2.  The Eustachian tube can also 
help to equilibrate gross pressure alterations, but likely plays a small role in minute-to-
minute ventilation of the middle ear3.   
 
Chronic middle ear inflammation can lead to sub-atmospheric middle ear pressure, 
tympanic membrane retraction, and/or middle ear effusion, and thus disable the middle ear 
gas pocket.   Re-establishment of middle ear ventilation is critical to the success of 
functional middle ear surgery4-6. The most common operation for restoration of hearing is 
the insertion of a grommet (ventilation tube), which reliably eliminates effusion in glue ear 
(chronic otitis media with effusion, COME).  The therapeutic effect of this procedure is 
thought to be rheological, whereby creation of a vent reduces fluid inertia, allowing effusion 
to be cleared down the Eustachian tube by the ciliary apparatus of the protympanum.  
Aspiration of effusion at the time of grommet insertion is not necessary7.   
 
However, a number of lines of evidence suggest that grommets moderate the inflammatory 
process in addition to, or in place of, any rheological effect that may occur.  Performing 
myringotomy and aspiration without intubation of the tympanic membrane leads to a rapid 
reaccumulation of effusion in children with COME8.  Recurrence of effusion still occurs in 
20-30% of children once grommets extrude9-12, but retrospective case series suggest that 
the risk of recurrence is inversely related to the duration of ventilation13 14.  There is also 
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endoscopic15 and histological16 17 evidence that resolution of middle ear inflammation is 
proportional to the duration of ventilation.  
 
We have previously suggested that some, or even the main therapeutic effect of middle ear 
ventilation may be through alleviation of tissue hypoxia18.  Hypoxia is a common finding in 
chronically inflamed microenvironments19 20, coordinated through the transcription factor 
hypoxia inducible factor (HIF).  Our group has explored the role of tissue hypoxia in the 
chronically inflamed middle ear by exploitation of the genetically altered Junbo21 and Jeff22 
mouse models of chronic otitis media18.  We have shown that systemic administration of 
pimodinazole (PIMO, a marker of tissues with an oxygen tension below 10 torr23) labels 
leucocytes in the exudate of the inflamed middle ear of both Junbo and Jeff mice, and also the 
middle ear mucosa in the Junbo mouse. Fluorescence-activated cell analysis confirms 
hypoxia in viable and apoptotic polymorphonuclear cells in the effusion, and transcriptome 
and proteome analysis of effusion reveals upregulation of a number of HIF responsive genes, 
notably in the signaling protein vascular endothelial growth factor (VEGF), a key executor of 
HIF response.   
 
Here we use the Junbo mouse model to investigate our hypothesis that the medium to long-
term beneficial effect of middle ear ventilation may be through alleviation of cellular 
hypoxia in the chronically inflamed middle ear.  Specifically, we demonstrate that surgical 
myringotomy leads to reduction of mucoperiosteal inflammatory thickening, and loss of 
PIMO labelling in operated ears. 
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Materials and Methods 
Mice 
Wild type (WT +/+) and heterozygote Junbo (Jbo/+) mice (hereafter referred to as Junbo 
mice) on a congenic C3H/HeH background were generated and maintained as 
previously described. Junbo phenotype is characterised by the spontaneous 
development of chronic inflammatory disease that is anatomically restricted to the ME18. 
 
Establishing duration of myringotomy patency in the mouse 
Surgical myringotomy has not previously been reported in the mouse.  We performed 
myringotomy on WT C3H/HeH mice (aged 6-9 weeks) to establish normal duration of 
patency.  Mice were anaesthetized by intraperitoneal injection of 10mg/kg xylazine and 
100mg/kg ketamine. The posterior pars tensa of the left ear was incised using a disposable 
myringotome (Exmoor plastics, UK) under direct vision with an operating microscope.   We 
always operated on the left ear because this was technically easier for our right-handed 
surgeon. Anaesthetic was reversed with 5mg/kg atipamezole hydrochloride.  Mice were 
subsequently euthanized with an overdose of intraperitoneal barbiturate at time points of 3, 
5, 7, and 10 days post-operatively (three mice for each time point).  The tympanic 
membranes were assessed using a binocular microscope.    
 
Myringotomy in three mouse cohorts 
We subsequently operated on the left ear of three cohorts of mice, all aged 6-10 wks-old:  
a) 10 WT controls who underwent myringotomy only 
b) 12 Junbo mice who underwent myringotomy only  
c) 15 Junbo mice who underwent myringotomy and removal of effusion using absorbent 
endodontic paper points. 
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The right ear was left unoperated to act as a control. Prior to operation all Junbo mice 
were assessed for bilateral visible evidence of tympanic membrane opacity, which we 
have previously shown to be a reliable marker of inflammatory effusion in the murine 
middle ear24.  
 
At intervals after myringotomy groups of mice were euthanized and skinned heads were 
fixed for 48 hours in 10% neutral buffered formalin, decalcified with Immunocal (Decal 
Corp) for 72 hours, and embedded in paraffin wax. 3µm sections were stained with 
haematoxylin and eosin.  Middle ear mucoperiosteal thickness was measured as 
previously described24 and compared between the operated left ear and the unoperated 
right ear using a paired sample t-test. 
 
Five days after left-sided unilateral myringotomy 3 WT and 3 Junbo mice were labeled 
for 3 hours in vivo by i.p. injection with 60 mg/kg pimonidazole (PIMO) dissolved in 100µl 
of sterile PBS. The mice were euthanized and 4µm histological sections of the middle 
ear were immunostained using anti-PIMO rabbit polyclonal PAb2627AP primary 
antibody at 1:200 dilution at room temperature for 60 mins (Hypoxprobe-1 Omni Kit; hpi 
Hypoxyprobe Inc., Burlington MA) followed by goat-anti rabbit IgG HRP conjugate 
secondary antibody at 1:50 dilution at room temperature for 30 mins (Dako P0448) 
according to the manufacturer’s instructions and with the following modifications. Antigen 
retrieval was by incubation at 60OC overnight in Vector high pH buffer (Vector 
Laboratories H-3301) to prevent detachment of tissue from the electrostatically charged 
slide; both primary and secondary antibodies were diluted in Dako antibody 
diluent (S0809); and visualisation was carried out using Liquid DAB+ (Dako K34811).  
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Ethical approval 
Full details of these studies were reviewed and approved by MRC Harwell ethical review 
committee. The humane care and use of mice in this study was carried out under the 
authority of the appropriate UK Home Office Project License.  
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Results 
We established that myringotomy in WT mice was reliably patent at up to five days post-
operatively (table 1) and used this time point in later experiments in Junbo mice. There 
were no significant complications or identifiable adverse effects from myringotomy. In each 
cohort data for mucoperiosteal thickness were normally distributed (Kolmogorov-Smirnov 
test).   
 
In WT mice (cohort a, n=10) there was no evidence that myringotomy induced mucosal 
inflammation.  The difference in mucoperiosteal thickness between left operated (19.9 +/- 
2.1 µm: mean and standard error of mean) and right unoperated (16 +/- 1.5 µm) ears in WT 
mice was not significant (figure 1).  There was no visible effusion in any of these ears. 
 
In Junbo mice (cohort b, n=12) there was histological evidence of reduced middle ear 
inflammation in response to myringotomy, although effects were variable.  Effusion volume 
was difficult to quantify precisely.  The cellularity of bulla fluid varied and histological 
processing resulted in uneven shrinkage of bulla fluid profiles. Nevertheless the qualitative 
impression was of reduced effusion in the operated compared to the unoperated ear, and in 
many cases appeared to have resolved completely.  Mucoperiosteal thickness in this cohort 
was less in the left operated ear (62.1 +/-9.1 µm) than the right unoperated ear (87.1 +/-9.1 
µm), p<0.05  (figure 1). 
 
In Junbo mice that underwent myringotomy with fluid removal (cohort c, n=15) we again 
found a variable response to surgery on qualitative histological assessment.  However, in 
the majority of cases (12/15 cases) there was no evidence of reappearance of effusion in the 
operated ear after bulla fluid removal at time of surgery, and there was a reduction in 
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inflammation, sometimes markedly so (figure 2).  Mean mucoperiosteal thickness in the left 
operated ear was significantly less (84.6 +/- 9.3 µm) than in the right unoperated ear (104.6 
+/- 8.3 µm), p<0.05 (figure 1). 
 
When data for cohort b and c were combined (i.e. all n=27 mice undergoing myringotomy 
with or without removal of effusion, analysed as a group) the mean mucoperiosteal 
thickening in the operated ear was significantly less (75.0 +/- 6.9 µm) compared to the 
unoperated ear (97.1 +/- 6.3µm), p<0.003 (figure 1). 
 
In the three WT mice PIMO labeling was only present in the healing myringotomy site, a 
feature also seen in the Junbo mice (figure 3). Two of three Junbo mice showed PIMO 
staining for hypoxia in the unoperated ear, labeling both middle ear mucoperiosteum and 
bulla exudate macrophages.  In both of these cases in the contralateral operated ear 
there was very little effusion and no PIMO labeling of the mucoperiosteum (figure 3).  
The other Junbo mouse had persistent effusion in both ears despite myringotomy, and 
here the macrophages in the effusion showed bilateral PIMO staining (but without PIMO 
labeling of the mucoperiosteum).  
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Discussion 
Macroscopic otitis media in Junbo heterozygote mice is evident from the accumulation of 
middle ear bulla fluids resulting in tympanic membrane opacity. In (n=54) 8-wk-old Junbo 
mice the incidence of bilateral fluids was 78%, unilateral fluids 13% and there was no 
overt bulla fluid in either ear of 9% of mice18.  
 
In the current experiments Junbo mice were assessed pre-operatively for the presence 
of bilateral fluids. The important assumptions in our experimental design were that 
myringotomy itself did not induce middle ear inflammation and bulla fluid effusion; that 
Junbo mice had pre-operative bilateral middle ear inflammation (and the bulla effusion 
was sufficiently cellular to drive middle ear hypoxia); and that myringotomy with or 
without fluid removal would significantly reduce bulla effusion volume and cellularity.  
 
We have shown here that myringotomy did not itself induce middle ear bulla effusion or 
mucoperiosteal thickening in WT mice but there was a proliferative epithelial repair 
response at the site of myringotomy incision.  There was a statistically significant 
reduction (~23%) in inflammatory thickening of the mucoperiosteum in the Junbo mouse 
five days after surgical myringotomy (with or without removal of effusion), the period in 
which the incision is patent.  We also found that myringotomy alone resulted in a 
qualitative reduction in the space occupied by bulla effusion, and that myringotomy with 
fluid removal resulted in a 80% reduction in the occurrence of bulla fluid five days post 
surgery.   The results of a small-scale in vivo labeling experiment with PIMO to identify 
sites of tissue and cellular hypoxia provide preliminary evidence that mucoperiosteal 
labeling was reduced in two of three operated Junbo middle ear bullae.  In these cases 
mucoperiosteal thickening was reduced and effusion was almost entirely removed.  In 
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the third Junbo mouse effusion was present in both the operated and unoperated ear, 
and here PIMO labeling of the effusion was present bilaterally.   
 
These data are consistent with our hypothesis that myringotomy reduces middle ear 
mucoperiosteum inflammation and leads to resolution of bulla effusion, and that an 
important biological mechanism of middle ear ventilation may be through alleviation of 
cellular hypoxia in chronically inflamed middle ear tissues. However the reduction of 
mucoperiosteal thickening and resolution of effusion was not universal after myringtomy 
and it is possible that more prolonged ventilation could improve the response to surgery 
in the Junbo mouse model. 
 
 
In the non-inflamed middle ear the partial pressures of oxygen, carbon dioxide, and 
nitrogen mirror those of venous blood, as a result of trans-mucosal gaseous exchange25-28. In 
our mouse models the chronically inflamed middle ear is hypoxic18 and human data also 
supports hypoxia pathway activation in COME, with elevated levels of VEGF reported in two 
studies29 30.  
 
Hypoxia is a common finding in inflamed environments.  Inflammation increases cellular 
energy demands, but simultaneously distances inflammatory cells from blood vessels due to 
cellular oedema and mucosal hyperplasia and extravasation of leucocytes into the bulla 
lumen.  Transcriptional regulation through HIF-VEGF pathways acts to compensate for the 
hypoxic environment, and restore tissue homeostasis to enable cellular survival under 
stress. However, persistent hypoxia signaling is known to be maladaptive, and can 
contribute to ongoing inflammation and tissue damage31 32.   
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Grommets expose the middle ear space to the relative hyperoxia33 of atmospheric oxygen, 
and this would presumably reverse tissue hypoxia, both of cells in the effusion and 
ultimately mucosal cells.  This may reduce inflammation and hence lead to the eventual 
resolution of middle ear effusion.  However, it is interesting to note that hypoxia pathways 
also have direct transcriptional activity on mucin production. The MUC5AC gene, which 
encodes one of the major mucins found in COME34, contains a highly conserved HIF binding 
site that acts as a transcriptional promoter. Experimental disruption of this binding site 
abolishes stimulated mucin secretion35.   Middle ear ventilation may therefore 
downregulate hypoxia pathways, which in turn eliminates one major driver for the 
transcription of the mucins that are the hallmark feature of COME. 
 
Alleviation of hypoxia may be an important adjunct to rheological effect of grommets. It is 
noteworthy that grommets have not been shown to affect the ventilatory function of the 
Eustachian tube in the short36, medium15 37 38, or long-term39, and so a purely physical action 
of grommets would seem an inadequate explanation as to why prolonged ventilation affects 
subsequent disease severity or recurrence.  
 
In this study we have used the Junbo21 mouse model of chronic otitis media.  The Junbo 
mouse spontaneously develops a highly penetrant chronic otitis media by 28 days of age, 
with a neutrophil and macrophage rich effusion. Junbo carries a point mutation at the 
Mecom locus (also known as the Mds1-Evi1 cluster), which may affect its interaction with 
TGF-ß40 41 JNK42 or NF-κB43 pathways.    Mouse models have made a considerable 
contribution to the experimental investigation of otitis media, because of their easy 
husbandry and the repertoire of techniques available to manipulate their genome, leading 
Page 12 of 24The Laryngoscope
The American Laryngological, Rhinological and Otological Society, Inc. 13
to the recovery of several mouse models of chronic otitis media (reviewed elsewhere44 45).  
However mouse models do have limitations46, including species differences in inflammatory 
response, which could limit the applicability of these models to human disease.  
Nevertheless, hypoxia pathway activation has been reported as a feature of human COME29 
30, and this compels us to believe that the Junbo mouse model is valid for exploration of 
human pathobiology. 
 
An extension of our study may be to look at the biological effects of a more extended 
duration of ventilation.  This could be achieved by laser myringotomy47-54 or by application 
of mitomycin-C55-59 to the incision, but these methods probably only slightly prolong 
patency of myringotomy and may in themselves contribute to inflammation.    
 
 
Conclusion 
We have undertaken the first animal study to investigate the biological effects of ventilation 
in chronic otitis media.  Using the Junbo mouse model, we have shown that surgical 
ventilation reduces inflammatory thickening of the middle ear mucoperiosteum, and that 
this may be due to alleviation of tissue hypoxia in the middle ear. Induction of chronic otitis 
media in larger species through bacterial challenge or genetic engineering may enable our 
studies to be repeated and extended to include intubation of the tympanic membrane. 
 
Grommets are the only treatment known to reliably lead to resolution of effusion in COME11.  
If, as we propose, their therapeutic effect is through alleviation of tissue hypoxia, it suggests 
that in the future their therapeutic benefit could be replaced with targeted molecular 
therapy based on hypoxia pathways.  Indeed, targeting hypoxia pathways with VEGF 
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receptor inhibitors moderates hearing loss in our mouse models of chronic otitis media18.  
The findings presented here suggest this may be a fruitful avenue to pursue in man, in place 
of surgical ventilation. 
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Table 1:  
Macroscopic patency of myringotomy in WT mice up to 10 days after incision. Unilateral 
surgery was performed on three mice for each time-point of two, five seven, and ten days 
post surgery.   
 
Days post myringotomy Proportion patent 
2 3/3 
5 3/3 
7 1/3 
10 0/3 
 
 
 
 
 
 
 
 
  
Page 20 of 24The Laryngoscope
The American Laryngological, Rhinological and Otological Society, Inc. 21
Figure 1: 
Mucoperiosteal thickness in the operated (myringotomy) and non-operated ears of the 
mice: WT mice (cohort a), Junbo mice (cohort b) and Junbo mice treated with myringtomy 
and removal  of effusion (cohort c).  p-values refer to a paired sample t-test. ns = not 
significant. 
 
Figure 2:  
The histology of the middle ear of Junbo mice five days post myringotomy and removal 
of the bulla effusion. 
 
(A) In the majority of cases there is minimal recurrence of effusion (e); (B) in a minority 
of cases myringotomy did not effectively reduce bulla effusion.  Note thickening of 
tympanic membrane results from epithelial and stromal hyperplasia at the site of surgical 
myringotomy (s).  A and B scale bar = 500 µm 
 
Figure 3:  
Hypoxia labeling with PIMO of the middle ear in the  Junbo mouse is reduced five days 
post myringotomy and removal of effusion.  
 
(A and C) In two Junbo mice the operated ear has much reduced effusion (e) and  
reduced inflammatory thickening of the mucoperiosteum (m) compared to (B and D) the 
corresponding contralateral unoperated ear where both the mucoperiosteum and 
leucocytes within the effusion are labeled with the hypoxia marker PIMO (arrows indicate 
cells with brown DAB staining).(E and F) The healing surgical myringotomy site is 
labeled with PIMO in both WT (E) and (F) Junbo mice. A-D scale bar = 100 µm; E and F 
scale bar = 200 µm. 
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